242 related articles for article (PubMed ID: 15952098)
21. Clarithromycin resistance and female gender affect Helicobacter pylori eradication failure in chronic gastritis.
Chang YW; Ko WJ; Oh CH; Park YM; Oh SJ; Moon JR; Cho JH; Kim JW; Jang JY
Korean J Intern Med; 2019 Sep; 34(5):1022-1029. PubMed ID: 29898576
[TBL] [Abstract][Full Text] [Related]
22. Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection.
Gawrońska-Szklarz B; Wrześniewska J; Starzyńska T; Pawlik A; Safranow K; Ferenc K; Droździk M
Eur J Clin Pharmacol; 2005 Jul; 61(5-6):375-9. PubMed ID: 15976989
[TBL] [Abstract][Full Text] [Related]
23. Influence of smoking and CYP2C19 genotypes on H. pylori eradication success.
Suzuki T; Matsuo K; Sawaki A; Wakai K; Hirose K; Ito H; Saito T; Nakamura T; Yamao K; Hamajima N; Tajima K
Epidemiol Infect; 2007 Jan; 135(1):171-6. PubMed ID: 16740190
[TBL] [Abstract][Full Text] [Related]
24. Modified allele-specific primer-polymerase chain reaction method for analysis of susceptibility of Helicobacter pylori strains to clarithromycin.
Furuta T; Soya Y; Sugimoto M; Shirai N; Nakamura A; Kodaira C; Nishino M; Okuda M; Okimoto T; Murakami K; Fujioka T; Hishida A
J Gastroenterol Hepatol; 2007 Nov; 22(11):1810-5. PubMed ID: 17914955
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype.
Lee SB; Park SJ; Ryu JK; Lee JK; Kim HJ; Bae JS; Jung HS; Park SM
Korean J Gastroenterol; 2003 Dec; 42(6):468-75. PubMed ID: 14695703
[TBL] [Abstract][Full Text] [Related]
26. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori.
Furuta T; Shirai N; Kodaira M; Sugimoto M; Nogaki A; Kuriyama S; Iwaizumi M; Yamade M; Terakawa I; Ohashi K; Ishizaki T; Hishida A
Clin Pharmacol Ther; 2007 Apr; 81(4):521-8. PubMed ID: 17215846
[TBL] [Abstract][Full Text] [Related]
27. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole.
Furuta T; Shirai N; Watanabe F; Honda S; Takeuchi K; Iida T; Sato Y; Kajimura M; Futami H; Takayanagi S; Yamada M; Ohashi K; Ishizaki T; Hanai H
Clin Pharmacol Ther; 2002 Oct; 72(4):453-60. PubMed ID: 12386647
[TBL] [Abstract][Full Text] [Related]
28. Correlation of CYP2C19 genetic polymorphisms with helicobacter pylori eradication in patients with cirrhosis and peptic ulcer.
Lay CS; Lin CJ
J Chin Med Assoc; 2010 Apr; 73(4):188-93. PubMed ID: 20457439
[TBL] [Abstract][Full Text] [Related]
29. Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin.
Furuta T; Shirai N; Takashima M; Xiao F; Hanai H; Nakagawa K; Sugimura H; Ohashi K; Ishizaki T
Pharmacogenetics; 2001 Jun; 11(4):341-8. PubMed ID: 11434512
[TBL] [Abstract][Full Text] [Related]
30. Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication.
Yang JC; Wang HL; Chern HD; Shun CT; Lin BR; Lin CJ; Wang TH
Pharmacotherapy; 2011 Mar; 31(3):227-38. PubMed ID: 21361732
[TBL] [Abstract][Full Text] [Related]
31. [Concomitant dosing of a H2 receptor antagonist (H2RA) with a triple therapy increases the cure rate of Helicobacter pylori infection].
Okudaira K; Miura S; Furuta T; Sugimoto M; Shirai N
Nihon Rinsho; 2005 Nov; 63 Suppl 11():391-6. PubMed ID: 16363566
[No Abstract] [Full Text] [Related]
32. Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers.
Aoyama N; Tanigawara Y; Kita T; Sakai T; Shirakawa K; Shirasaka D; Kodama F; Okumura K; Kasuga M
J Gastroenterol; 1999; 34 Suppl 11():80-3. PubMed ID: 10616772
[TBL] [Abstract][Full Text] [Related]
33. Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19.
Okudaira K; Furuta T; Shirai N; Sugimoto M; Miura S
Aliment Pharmacol Ther; 2005 Feb; 21(4):491-7. PubMed ID: 15710002
[TBL] [Abstract][Full Text] [Related]
34. Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin.
Kawabata H; Habu Y; Tomioka H; Kutsumi H; Kobayashi M; Oyasu K; Hayakumo T; Mizuno S; Kiyota K; Nakajima M; Kimoto K; Inokuchi H; Kawai K
Aliment Pharmacol Ther; 2003 Jan; 17(2):259-64. PubMed ID: 12534411
[TBL] [Abstract][Full Text] [Related]
35. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Furuta T; Shirai N; Sugimoto M; Nakamura A; Hishida A; Ishizaki T
Drug Metab Pharmacokinet; 2005 Jun; 20(3):153-67. PubMed ID: 15988117
[TBL] [Abstract][Full Text] [Related]
36. Improved efficacy of proton pump inhibitor - amoxicillin - clarithromycin triple therapy for Helicobacter pylori eradication in low clarithromycin resistance areas or for tailored therapy.
Prasertpetmanee S; Mahachai V; Vilaichone RK
Helicobacter; 2013 Aug; 18(4):270-3. PubMed ID: 23356886
[TBL] [Abstract][Full Text] [Related]
37. Gastric wash-based molecular testing for antibiotic resistance in Helicobacter pylori.
Baba S; Oishi Y; Watanabe Y; Oikawa R; Morita R; Yoshida Y; Hiraishi T; Maehata T; Nagase Y; Fukuda Y; Nakazawa M; Ishigouoka S; Hattori N; Suzuki H; Toyota M; Niwa H; Suzuki M; Itoh F
Digestion; 2011; 84(4):299-305. PubMed ID: 22057261
[TBL] [Abstract][Full Text] [Related]
38. Triple therapy with lansoprazole, clarithromycin, and amoxicillin for the cure of Helicobacter pylori infection: a short report.
Riff DS; Kidd S; Rose P; Haber M; Weissfeld A; Siepman N
Helicobacter; 1996 Dec; 1(4):238-42. PubMed ID: 9398874
[TBL] [Abstract][Full Text] [Related]
39. Influence of CYP2C19 functional polymorphism on Helicobacter pylori eradication.
Ozdil B; Akkiz H; Bayram S; Bekar A; Akgöllü E; Sandikçi M
Turk J Gastroenterol; 2010 Mar; 21(1):23-8. PubMed ID: 20533108
[TBL] [Abstract][Full Text] [Related]
40. Low Helicobacter pylori primary resistance to clarithromycin in gastric biopsy specimens from dyspeptic patients of a city in the interior of São Paulo, Brazil.
Suzuki RB; Lopes RA; da Câmara Lopes GA; Hung Ho T; Sperança MA
BMC Gastroenterol; 2013 Dec; 13():164. PubMed ID: 24305035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
